Literature DB >> 27322025

Other age groups than children need to be considered as carriers of Streptococcal pneumoniae serotypes.

Hans-Christian Slotved1.   

Abstract

We need to raise the issue that focus on children as the only carriage group for pneumococci is not optimal; we need to consider that other age groups might also be carriers of pneumococcal serotypes causing invasive pneumococcal diseases (IPD) in unvaccinated age groups. The pneumococcal conjugate vaccines (PCV) have successfully removed IPD from vaccinated children. Studies have shown an effect of PCV reducing the pneumococcal carriage of PCV serotypes in children. The status for several countries having used PCV for many years is that they do not see PCV serotypes neither carried nor as a cause of IPD in children. PCV vaccination of children has shown a herd protection effect in unvaccinated groups as a reduction in IPD cases caused by PCV serotypes. However, not all PCV serotypes have disappeared as the cause of IPD in the unvaccinated age groups. The author therefore believes that if we are to see PCV serotypes disappear as a cause of IPD in unvaccinated age groups, we need to perform further carriage studies to examine carriage in other age groups. Alternatively, all age groups should be vaccinated against pneumococci to eliminate IPD caused by PCV serotypes from possible hidden carriers.

Entities:  

Keywords:  Carriage groups; Invasive pneumococcal disease (IPD); Pneumococcal vaccines; Streptococcus pneumoniae; Vaccination strategy

Mesh:

Substances:

Year:  2016        PMID: 27322025      PMCID: PMC5084994          DOI: 10.1080/21645515.2016.1197451

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  36 in total

1.  Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Authors:  Anneke Steens; Marianne A Riise Bergsaker; Ingeborg S Aaberge; Karin Rønning; Didrik F Vestrheim
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

2.  Pneumococcal vaccination in older adults in the era of childhood vaccination: Public health insights from a Norwegian statistical prediction study.

Authors:  Anneke Steens; Didrik F Vestrheim; Birgitte Freiesleben de Blasio
Journal:  Epidemics       Date:  2015-01-19       Impact factor: 4.396

3.  Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.

Authors:  Pauline A Waight; Nicholas J Andrews; Shamez N Ladhani; Carmen L Sheppard; Mary P E Slack; Elizabeth Miller
Journal:  Lancet Infect Dis       Date:  2015-03-20       Impact factor: 25.071

4.  Trends in asymptomatic nasopharyngeal colonization with streptococcus pneumoniae after introduction of the 13-valent pneumococcal conjugate vaccine in Calgary, Canada.

Authors:  Leah J Ricketson; Melissa L Wood; Otto G Vanderkooi; Judy C MacDonald; Irene E Martin; Walter H B Demczuk; James D Kellner
Journal:  Pediatr Infect Dis J       Date:  2014-07       Impact factor: 2.129

5.  Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada.

Authors:  I Feavers; I Knezevic; M Powell; E Griffiths
Journal:  Vaccine       Date:  2009-04-17       Impact factor: 3.641

6.  Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.

Authors:  Zitta Barrella Harboe; Tine Dalby; Daniel M Weinberger; Thomas Benfield; Kåre Mølbak; Hans Christian Slotved; Camilla H Suppli; Helle Bossen Konradsen; Palle Valentiner-Branth
Journal:  Clin Infect Dis       Date:  2014-07-16       Impact factor: 9.079

7.  The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark.

Authors:  Hans-Christian Slotved; Tine Dalby; Steen Hoffmann
Journal:  Vaccine       Date:  2016-01-06       Impact factor: 3.641

8.  Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.

Authors:  Michael G Bruce; Rosalyn Singleton; Lisa Bulkow; Karen Rudolph; Tammy Zulz; Prabhu Gounder; Debby Hurlburt; Dana Bruden; Thomas Hennessy
Journal:  Vaccine       Date:  2015-08-04       Impact factor: 3.641

9.  Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status.

Authors:  Chamira Rodrigo; Thomas Bewick; Carmen Sheppard; Sonia Greenwood; Vanessa Macgregor; Caroline Trotter; Mary Slack; Robert George; Wei Shen Lim
Journal:  Thorax       Date:  2013-09-18       Impact factor: 9.139

Review 10.  A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older.

Authors:  A Steens; D F Vestrheim; I S Aaberge; B S Wiklund; J Storsaeter; M A Riise Bergsaker; K Rønning; E Furuseth
Journal:  Epidemiol Infect       Date:  2014-06-16       Impact factor: 4.434

View more
  6 in total

1.  Molecular surveillance on Streptococcus pneumoniae carriage in non-elderly adults; little evidence for pneumococcal circulation independent from the reservoir in children.

Authors:  Anne L Wyllie; Lidewij W Rümke; Kayleigh Arp; Astrid A T M Bosch; Jacob P Bruin; Nynke Y Rots; Alienke J Wijmenga-Monsuur; Elisabeth A M Sanders; Krzysztof Trzciński
Journal:  Sci Rep       Date:  2016-10-07       Impact factor: 4.379

2.  Probiotics and carriage of Streptococcus pneumoniae serotypes in Danish children, a double-blind randomized controlled trial.

Authors:  Sine Fjeldhøj; Rikke Pilmann Laursen; Anni Larnkjær; Christian Mølgaard; Kurt Fuursted; Karen Angeliki Krogfelt; Hans-Christian Slotved
Journal:  Sci Rep       Date:  2018-10-15       Impact factor: 4.379

3.  Molecular characterization and epidemiology of Streptococcus pneumoniae serotype 24F in Denmark.

Authors:  Ioanna Drakaki Kavalari; Kurt Fuursted; Karen A Krogfelt; H-C Slotved
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

4.  Pneumococcal Colonization in Healthy Adult Research Participants in the Conjugate Vaccine Era, United Kingdom, 2010-2017.

Authors:  Hugh Adler; Elissavet Nikolaou; Katherine Gould; Jason Hinds; Andrea M Collins; Victoria Connor; Caz Hales; Helen Hill; Angela D Hyder-Wright; Seher R Zaidi; Esther L German; Jenna F Gritzfeld; Elena Mitsi; Sherin Pojar; Stephen B Gordon; Adam P Roberts; Jamie Rylance; Daniela M Ferreira
Journal:  J Infect Dis       Date:  2019-05-24       Impact factor: 5.226

5.  It Takes Two to Tango: Combining Conventional Culture With Molecular Diagnostics Enhances Accuracy of Streptococcus pneumoniae Detection and Pneumococcal Serogroup/Serotype Determination in Carriage.

Authors:  Willem R Miellet; Janieke van Veldhuizen; David Litt; Rob Mariman; Alienke J Wijmenga-Monsuur; Paul Badoux; Tessa Nieuwenhuijsen; Rebecca Thombre; Sanaa Mayet; Seyi Eletu; Carmen Sheppard; Marianne Alice van Houten; Nynke Y Rots; Elizabeth Miller; Norman K Fry; Elisabeth A M Sanders; Krzysztof Trzciński
Journal:  Front Microbiol       Date:  2022-04-18       Impact factor: 6.064

6.  The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination.

Authors:  Hans-Christian Slotved; Tine Dalby; Zitta Barrella Harboe; Palle Valentiner-Branth; Victoria Fernandez de Casadevante; Laura Espenhain; Kurt Fuursted; Helle Bossen Konradsen
Journal:  Heliyon       Date:  2016-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.